Skip to contentSkip to Braille Studio

Library / Laws / 119th Congress / Senate Bills / S. 1096

S. 1096

To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.

Print stageDateSize⠃
Introduced in Senate2025-03-2421.6K⠃⠗⠋
Reported in Senate2025-04-1042.8K⠃⠗⠋